OmniAb, Inc. (OABIW) stock
OABIWNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31Also trades as OABI
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 10/309% above fair value
$0.41−0.01 (-2.38%)
Close on Oct 30, 2026Market cap $742.95MP/E –Yield –
OmniAb operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
OmniAb's operating income for the twelve months ending Sep 30, 2026 was -$46.60M. For fiscal 2025 it was -$68.97M. The highest annual figure on record is -$26.65M in fiscal 2022.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$68.97M | – |
| FY2024 | Dec 31, 2024 | -$74.50M | – |
| FY2023 | Dec 31, 2023 | -$69.42M | – |
| FY2022 | Dec 31, 2022 | -$26.65M | – |
| FY2021 | Dec 31, 2021 | -$35.61M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$16.37M | – |
| Q2 FY2026 | Jun 30, 2026 | -$6.64M | – |
| Q1 FY2026 | Mar 31, 2026 | -$7.83M | – |
| Q4 FY2025 | Dec 31, 2025 | -$15.77M | – |
| Q3 FY2025 | Sep 30, 2025 | -$18.14M | – |
| Q2 FY2025 | Jun 30, 2025 | -$16.22M | – |
| Q1 FY2025 | Mar 31, 2025 | -$18.84M | – |
| Q4 FY2024 | Dec 31, 2024 | -$15.88M | – |
| Q3 FY2024 | Sep 30, 2024 | -$19.76M | – |
| Q2 FY2024 | Jun 30, 2024 | -$16.31M | – |
| Q1 FY2024 | Mar 31, 2024 | -$22.55M | – |
| Q4 FY2023 | Dec 31, 2023 | -$21.21M | -334.3% |
| Q3 FY2023 | Sep 30, 2023 | -$20.32M | – |
| Q2 FY2023 | Jun 30, 2023 | -$19.45M | – |
| Q1 FY2023 | Mar 31, 2023 | -$8.45M | – |
| Q4 FY2022 | Dec 31, 2022 | $9.05M | – |
| Q3 FY2022 | Sep 30, 2022 | -$14.91M | – |
| Q2 FY2022 | Jun 30, 2022 | -$12.57M | – |
| Q1 FY2022 | Mar 31, 2022 | -$8.22M | – |
| Q3 FY2021 | Sep 30, 2021 | -$170.58K | – |
| Q2 FY2021 | Jun 30, 2021 | -$2.19K | – |